Prolia and XGEVA Attorneys
Experienced in Drug Product Liability Cases
Rheingold, Valet, Rheingold, McCartney & Giuffra LLP are experienced in handling drug product liability cases nationwide and we're aggressively investigating Prolia and XGEVA cases.
The drugs Prolia and XGEVA (denosumab), manufactured by Amgen, are used to treat osteoporosis and to prevent fractures. Unfortunately, a side effect of Prolia and XGEVA is damage to bones as well as other problems. Specifically, these drugs could lead to:
- Atypical Femur Fractures, and other Atypical Fractures
- Severe Suppression in Bone Turnover
Similar to bisphosphonate drugs (ie Fosamax, Boniva, and Actonel), Prolia and XGEVA work by suppressing bone turnover which is thought to increase the user's bone density. However Prolia and XGEVA are not bisphosphonates but are rather monoclonal antibodies that act as RANKL inhibitors which mediate osteoclast activation. The injuries are typically limited to the jaw and femur because the drugs tend to "target" bones that have been subjected to heaviest impact, namely our femurs/hips (from walking) and jaws (from chewing).
Contact the experienced attorneys at Rheingold, Valet, Rheingold, McCartney & Giuffra LLP to speak with an attorney about Prolia and your injuries.
Some drugs that inhibit bone turnover can damage femurs to such an extent that femur/hip breaks caused by them usually occur during routine activity like walking to a mailbox or even just standing. If you suspect that you or a loved one has experienced a fractured or broken femur following the use of Prolia or XGEVA, contact the New York product liability law firm of Rheingold, Valet, Rheingold, McCartney & Giuffra LLP. Our firm has vast experience in handling product liability matters and have the knowledge, experience, and resources to go up against the biggest drug companies like Amgen, the company who manufactures both these drugs.
The FDA has required bisphosphonates drugs to add warnings about long term use and atypical fractures, Amgen has not included such a warning on their label for Prolia or XGEVA. Some say it is just a matter of time before the evidence suggests that Prolia and XGEVA cause atypical fractures, and most likely for the same reason Fosamax, Boniva, and Actonel cause femur fractures.
Our firm filed one of the first bisphosphonate femur fracture cases in February, 2009, almost two years before the FDA required warnings about the injury. In the case of Fosamax we are reviewing and filing cases in a coordinated action with other firms in order combine forces for the strongest possible litigation. Drug companies selling osteoporosis medications have attempted to thwart litigation, but our firm and the courts are now pushing the litigation based on the continued findings of medical studies. Through written discovery demands on the drug companies, we will learn more about what their actual knowledge was of the nine femur fracture victims reported in 2005 (some of which obviously happened before 2005), which is five years before the warning was added to bisphosphonates. More information came out in 2008, and finally now there are multiple medical journal articles linking atypical fractures to suppressed bone turnover. It is surprising that even with all of the information linking drugs that suppress bone turnover to atypical fractures that Amgen has still neglected to add a warning regarding what they anticipate to be a blockbuster drug in Prolia.
For knowledgeable legal help in New York regarding Prolia femur and bone injuries, contact the lawyers of Rheingold, Valet, Rheingold, McCartney & Giuffra LLP at 888-335-9457.
Rheingold, Valet, Rheingold, McCartney & Giuffra LLP offers free initial consultations, works on a contingency fee basis and is conveniently located in Midtown Manhattan. To contact us, call 888-335-9457.